

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Use of alternate coreceptors on primary cells by two HIV-1 isolates

Citation for published version:

Cilliers, T, Willey, S, Sullivan, WM, Patience, T, Pugach, P, Coetzer, M, Papathanasopoulos, M, Moore, JP, Trkola, A, Clapham, P & Morris, L 2005, 'Use of alternate coreceptors on primary cells by two HIV-1 isolates', Virology, vol. 339, no. 1, pp. 136-44. https://doi.org/10.1016/j.virol.2005.05.027

Digital Object Identifier (DOI):

10.1016/j.virol.2005.05.027

Link: Link to publication record in Edinburgh Research Explorer

Document Version: Publisher's PDF, also known as Version of record

Published In: Virology

Publisher Rights Statement: Copyright 2005 Elsevier Inc.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Available online at www.sciencedirect.com



Virology 339 (2005) 136-144

VIROLOGY

www.elsevier.com/locate/yviro

Use of alternate coreceptors on primary cells by two HIV-1 isolates

Tonie Cilliers^a, Samantha Willey^b, W. Mathew Sullivan^b, Trudy Patience^a, Pavel Pugach^c, Mia Coetzer^a, Maria Papathanasopoulos^{a,1}, John P. Moore^c, Alexandra Trkola^d, Paul Clapham^b, Lynn Morris^{a,*}

^aAIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa ^bCenter for AIDS Research, Program in Molecular Medicine, Department of Molecular Genetics and Microbiology,

University of Massachusetts Medical School, Worcester, MA 01605, USA

^cJoan and Sanford I. Weill Medical College of Cornell University, Department of Microbiology and Immunology, New York, NY 10021, USA ^dDivision of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland

> Received 14 March 2005; returned to author for revision 30 March 2005; accepted 25 May 2005 Available online 29 June 2005

Abstract

Two HIV-1 isolates (CM4 and CM9) able to use alternate HIV-1 coreceptors on transfected cell lines were tested for their sensitivity to inhibitors of HIV-1 entry on primary cells. CM4 was able to use CCR5 and Bob/GPR15 efficiently in transfected cells. The R5 isolate grew in $\Delta 32/\Delta 32$ CCR5 PBMC in the absence or presence of AMD3100, a CXCR4-specific inhibitor, indicating that it uses a receptor other than CCR5 or CXCR4 on primary cells. It was insensitive to the CCR5 entry inhibitors RANTES and PRO140, but was partially inhibited by vMIP-1, a chemokine that binds CCR3, CCR8, GPR15 and CXCR6. The coreceptor used by this isolate on primary cells is currently unknown. CM9 used CCR5, CXCR4, Bob/GPR15, CXCR6, CCR3, and CCR8 on transfected cells and was able to replicate in the absence or presence of AMD3100 in $\Delta 32/\Delta 32$ CCR5 PBMC. It was insensitive to eotaxin, vMIP-1 and I309 when tested individually, but was inhibited completely when vMIP-1 or I309 was combined with AMD3100. Both I309 and vMIP-1 bind CCR8, strongly suggesting that this isolate can use CCR8 on primary cells. Collectively, these data suggest that some HIV-1 isolates can use alternate coreceptors on primary cells, which may have implications for strategies that aim to block viral entry.

© 2005 Elsevier Inc. All rights reserved.

Keywords: HIV-1; Alternate coreceptors; CCR8; Bob/GPR15

Introduction

The human immunodeficiency virus type 1 (HIV-1) gains entry into a cell by binding to host cell surface receptors. This interaction is a sequential process and can be defined in three stages: namely, CD4 binding, coreceptor binding and the fusion process. The two most important coreceptors are CCR5 and CXCR4, and all HIV-

* Corresponding author. Fax: +27 11 386 6333.

E-mail address: lynnm@nicd.ac.za (L. Morris).

1 isolates tested to date use one or both (Doms and Moore, 2000). A few rare isolates can also use other coreceptors present on coreceptor-transfected cell-lines, including CCR1, CCR2b, CCR3, Bob/GPR15, CXCR6 (STRL33) and CCR8 (Cilliers et al., 2003; Deng et al., 1997; Edinger et al., 1998; Pohlmann et al., 1999; Xiao et al., 1998). Some of these receptors such as CXCR6 and CCR8 have been shown to function as HIV entry coreceptors on primary cells in vitro (Lee et al., 2000; Sharron et al., 2000; Zhang et al., 2000, 2001). Further evidence that some isolates can use alternate coreceptors comes from studies where both major coreceptors are either absent or blocked. In this regard, the use of PBMC with a 32-base pair deletion in CCR5 ($\Delta 32/\Delta 32$ CCR5) in the presence of a CXCR4 inhibitor has proven particularly useful (Aze-

¹ Present address: HIV Pathogenesis Research Laboratory, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, Johannesburg, South Africa.

^{0042-6822/\$ -} see front matter © 2005 Elsevier Inc. All rights reserved. doi:10.1016/j.virol.2005.05.027

vedo-Pereira et al., 2003; Willey et al., 2003; Zhang et al., 2000). Identification of alternative HIV-1 coreceptors is hampered by the lack of suitable ligands although in some instances chemokines have been used to provide suggestive evidence (Willey et al., 2003). Collectively, these data demonstrate that some rare isolates can exploit alternate coreceptors on primary cells in vitro, although whether such receptors are used by HIV-1 in vivo remains unclear (Sharron et al., 2000; Willey et al., 2003; Zhang and Moore, 1999; Zhang et al., 2001).

The ability of isolates to use particular coreceptors for viral entry can be determined by the use of inhibitors that block specific receptors (Moore et al., 2004). Inhibitors of CCR5 and CXCR4 have been shown to be highly effective in vitro and are being developed for clinical use (Moore and Doms, 2003; Seibert and Sakmar, 2004). Inhibitors binding to CCR5 include PRO140, a monoclonal antibody (Mab) directed at CCR5, and RANTES, a natural ligand for CCR5 (Olson et al., 1999; Wu et al., 1997). AMD3100 is a small molecule inhibitor able to bind to CXCR4 and prevent CXCR4-using HIV-1 isolates from infecting cells (Donzella et al., 1998; Schols et al., 1997). Blocking CCR5 is of particular interest as this is the coreceptor used during the initial phases of HIV-1 infection and R5 viruses can persist until the end stage (Douek et al., 2003; Moore et al., 2004). The ability of some viral isolates to use alternate coreceptors could impact on the efficacy of entry inhibitors and possibly also HIV pathogenesis. Hence, it is relevant to identify and characterize HIV isolates able to use alternate coreceptors on primary cells.

A previous study reported that viral macrophage inflammatory protein-1 (vMIP-1), a promiscuous chemokine expressed by Human Herpes Virus 8, could bind to a range of coreceptors, including CCR8, GPR1, CXCR6 and to a lesser extent Bob/GPR15 (Dairaghi et al., 1999; Willey et al., 2003). This chemokine has been shown to prevent HIV-1 infection of some isolates on primary cells when the major coreceptors are absent or blocked. This suggests that vMIP-1 might be useful in identifying alternate coreceptors that could be used by HIV-1 isolates (Willey et al., 2003). The aim of this study was to further investigate how two unusual HIV-1 isolates can use alternate coreceptors on primary cells, by using chemokines with defined receptor binding profiles.

Results

Coreceptor usage of CM4 and CM9

Two HIV-1 isolates from patients with cryptococcal meningitis, a severe AIDS defining condition, were selected for this study. CM9 is an HIV-1 subtype C R5X4 isolate able to use CCR5, CXCR4, CCR3, CXCR6 and Bob/GPR15 to replicate in transfected cell lines (Cilliers et al., 2003) (Table 1). While the efficiency with which CM9 used

Table 1	
Growth of CM4 and CM9 on coreceptor transfected cell lines	

Isolate	Biotype	Coreceptor usage (day 12 p24 ng/ml)					
		U87.CD4		GHOST.3			
		CCR5	CXCR4	Bob/GPR15	CCR3	CXCR6	
CM4	R5	70	<1	65	<1	<1	
CM9	R5X4	69	48	3	3	8.5	

Note. Replication levels between U87.CD4 cells and GHOST.3 cells may not be directly comparable.

the three minor coreceptors was considerably lower than for the two major coreceptors (i.e. CCR5 and CXCR4), their usage was highly reproducible on GHOST.3 cell lines. CM4, a complex recombinant R5 virus with subtype C-like envelope was able to use both CCR5 and Bob/GPR15 with equal efficiency on transfected cell lines (Table 1). This isolate was unable to use CXCR4, as judged by its inability to replicate in U87.CD4.CXCR4 or MT-2 cells. It was also unable to use CCR3, CXCR6 or CCR1. CCR1 was included as a negative control for both CM4 and CM9 (Table 1).

Both CM4 and CM9 were able to replicate in $\Delta 32/\Delta 32$ CCR5 PBMC efficiently although CM4 replicated to higher levels (84 ng/ml versus 10 ng/ml p24 in one representative experiment) (see also Figs. 2 and 3). The growth seen for CM9 in $\Delta 32/\Delta 32$ CCR5 PBMC is most likely related to the ability of this isolate to use CXCR4 (Cilliers et al., 2003). Since CM4 is unable to use CXCR4, growth in $\Delta 32/\Delta 32$ CCR5 PBMC must be due to an alternate receptor. Whether CM4 is using Bob/GPR15 to enter PBMC cannot be assessed at present as no inhibitor, including polyclonal antibodies, or natural ligands to block this coreceptor is available.

Use of CCR5 and CXCR4 inhibitors to determine coreceptor use

To further define coreceptor specificity of CM9 and CM4, specific inhibitors were used. The CCR5 inhibitors included the anti-CCR5 Mab PRO140 and the CC-chemokine RANTES. AMD3100 was also used to block CXCR4. The assays were performed on wt/wt CCR5 PHA-stimulated PBMC with a p24 antigen read-out on day 6. CM4 was not inhibited by either PRO140 or RANTES at the same concentrations that were active against other HIV-1 isolates (Table 2) (Cilliers et al., 2003; Trkola et al., 2001). This isolate was also insensitive to AMD3100, consistent with its inability to use CXCR4. Hence, neither CCR5 nor CXCR4 inhibitors were effective against CM4. In contrast, CM9 was sensitive to AMD3100 (97% inhibition on day 6, Table 2). However, like CM4, CM9 was insensitive to the CCR5 inhibitors. Thus, the major coreceptor of preference for this pleiotropic isolate is CXCR4 (Cilliers et al., 2003).

We next tested the ability of CM4 and CM9 to be inhibited by the fusion inhibitor Enfuvirtide, which is not

Table 2 Effect of CCR5, CXCR4 and fusion inhibitors on CM4 and CM9 replication in (wt/wt) CCR5 PBMC

Isolate	Biotype	% inhibition					
		PRO140 (167 nM)	RANTES (19 nM)	AMD3100 (500 nM)	Enfuvirtide (1 µg/ml)		
CM4	R5	33	24	4	99		
CM9	R5X4	36	34	97	100		

coreceptor-specific. Both isolates were fully sensitive to Enfuvirtide and were inhibited by >99% at 1 μ g/ml (Cilliers et al., 2004). This demonstrates that use of an alternate coreceptor does not radically alter the envelope-mediated fusion process.

Env sequence analysis of CM4 and CM9 grown in different cell lines

To determine if minor quasispecies were accounting for multiple coreceptor use, CM4 and CM9 were grown in different cell lines. The env genes were then sequenced and compared to those of the original infecting strain. CM4-P2 was grown in normal donor PBMC, $\Delta 32/\Delta 32$ CCR5 PBMC, and GHOST.3 cells expressing Bob/GPR15. The amino acid sequences of the expanded viruses were then compared to the original infecting stock (CM4-P1). All gp160 sequences from CM4-P2 grown in different cells were identical (Fig. 1A). When these sequences were compared to the earlier stock (CM4-P1), only a single amino acid change in the V3 region (T300N) was noted (Fig. 1A). Hence, the major viral population of CM4 uses both CCR5 and Bob/GPR15 as coreceptors on transfected cell lines as well as on $\Delta 32/\Delta 32$ CCR5 PBMC, suggesting that the same envelope glycoprotein configuration can use both CCR5 and Bob/GPR15. CM4 had a low overall charge of +3 in the V3 loop, which is more consistent with usage of CCR5 than of CXCR4 (Hoffman et al., 2002).

A similar analysis was done using CM9 grown in cell lines expressing CCR5, CXCR4, CCR3, CXCR6 and Bob/ GPR15, with the resulting sequences then compared to the original isolate grown in wt/wt PBMC. Distinct amino acid sequence changes in gp160 were noted between the selected populations, particularly in the V1/V2 and V3 regions of gp120, and in the cytoplasmic tail of gp41 (Fig. 1B). Viruses that grew in the CXCR6/Bonzo and CCR3 cell lines were virtually identical in sequence, and most similar to the viruses that grew in the CCR5 transfected cells. The sequence of the virus grown in CXCR4-expressing cells was identical to the original PBMC sequence and most similar to the virus that grew out of the Bob/GPR15 cells. Three changes were noted in the V3 crown region between these two populations. The viruses expanded on the CXCR4 or Bob/GPR15 cells had a GPRY motif while those grown in CCR5, CXCR6/Bonzo or CCR3 expressing cells had a GPGY sequence. There was no difference in the overall charge (+6) or number of amino acids in the V3 region of the different selected populations, so no prediction about coreceptor usage could be made from the genotype. An insertion in the cytoplasmic tail of the gp41 region was noted for almost all viruses grown in coreceptor-transfected cells except for those grown in CXCR4 transfected cells (Fig. 1B). This suggests that the original CM9 isolate comprised at least 2 distinct populations, one that uses CCR5, CXCR6 and CCR3 and a second that uses CXCR4 and Bob/GPR15. This mixed population may account for the usage of at least 2 different coreceptors by this isolate.

Inhibition assays on $\Delta 32/\Delta 32$ CCR5 PBMC

We next explored the ability of chemokines that act as natural ligands for alternate coreceptors to inhibit CM4 and CM9 replication in $\Delta 32/\Delta 32$ CCR5 PBMC. The chemokine vMIP-1 is a promiscuous chemokine secreted by Human Herpes Virus 8 that binds to CCR8, GPR1, Bob/GPR15 and CXCR6 (Dairaghi et al., 1999; Simmons et al., 2000; Willey et al., 2003). Eotaxin is the ligand for CCR3, and I309 is specific for CCR8. CM9 was grown in $\Delta 32/\Delta 32$ CCR5 PBMC in the presence of vMIP-1, I309 and eotaxin either singly or in combination with AMD3100. It was previously shown that CM9 could be inhibited by AMD3100 for up to 6 days on normal donor PBMC, consistent with its efficient use of CXCR4 for entry (Cilliers et al., 2003). However, in this study, we found that CM9 was eventually able to replicate in the presence of AMD3100 on $\Delta 32/\Delta 32$ CCR5 PBMC when the assay was extended beyond 6 days (Fig. 2A). When AMD3100 was combined with eotaxin, the natural ligand for CCR3, there was enhanced viral replication. vMIP-1 and I309 had no effect on CM9 replication when tested individually (Fig. 2A) but when they were combined with AMD3100, inhibition was complete (Fig. 2B). Since both I309 and vMIP-1 can bind to CCR8, CM9 may be using CCR8 to infect $\Delta 32/\Delta 32$ CCR5 PBMC in the presence of AMD3100. This was confirmed when CM9 was grown on NP2/CD4 cell lines expressing CCR8 (Fig. 4). Replication in these cells was as efficient as growth in NP2/ CD4 cells expressing either CCR5 or CXCR4.

CM4 was tested in $\Delta 32/\Delta 32$ CCR5 PBMC in the absence and presence of AMD3100, vMIP-1, I309 and CXCL16

Fig. 1. (A) Full-length envelope amino acid sequence alignment of CM4 grown in different cell lines and PBMC. The original culture supernatant is labeled CM4-P1. The regrown strain is labeled CM4-P2. CM4-P2 grown in PBMC (CM4-PBMC), Δ32/Δ32 CCR5 PBMC (CM4-Δ32) and GHOST.3.Bob cell line (CM4-Bob) is shown. The variable loops are highlighted in grey and amino acid changes are shown. Dots indicate identical amino acids. (B) Full-length envelope amino acid sequence of CM9 grown in different cell lines and PBMC (CM9-PBMC). CM9 was grown in U87.CD4.CXCR4 (CM9-X4), GHOST.3 transfected with Bob/GPR15 (CM9-Bob), U87.CD4.CCR5 (CM9-R5) and GHOST.3.CXCR6 (CM9-CXCR6) and CCR3 (CM9-R3), respectively. The variable loops are highlighted in grey and amino acid changes are shown. Dots indicate identical amino acid insertions.

V2

V1

А gp120



		A COMPANY DATED IN COLUMN 2 IN COLUMN	TO THE REMANDING	AVEL THOMAS TROS OF WIR		
CM4-P1 :	LTPLCVILNCSNVNVTSNGNTSSIKEAGEIKNCSFN	ATTEIRNKRKKVIALFIK	LDIVPLEDNSNDN:	STILINCHTSAITQACPRV	TFEPIPIHICAPAGIAILKCNNKTFNGTGPC	. : 240
CM4-PBMC						. : 240
CM4-32 :	· ·······			•••••		. : 240
CM4-Bob :	•••••••••••		• • • • • • • • • • • • • • • •	•••••	• • • • • • • • • • • • • • • • • • • •	. : 240
			V3			
	* 260 *	280 *	300	* 320	* 340 * 36	
CM4-P1 :	VSTVQCTHGIKPVVSTQLLLNGSLAEGEIIIRSENL	TDNTKTIIVHLNQSVNIT	CIRPTNNTRQSIR	GPGQVFFGTDVIGDIRQAH	NISKADWNKTLQGVSKKLIELFPNKKIEFK	S : 360
CM4-P2 :	• •••••••	Q	N	•••••		. : 360
CM4-PBMC			N	•••••		. : 360
CM4-Bob			N			. : 360
	V4				V5	
	* 380 *	400 *	420	* 440	* 460 * 48	0
CM4-P1 :	SGGDVEITTHSFNCGGEFFFCNTSGLFNSTWGKNDT	NRTIGTGTNENITLPCRI	KQIVNMWQRVGQA:	YAPPIQGIIRCESNITGILI	TRDGGNNNSSNNNNDTEIFRPGGGDMRDNW	S : 480
CM4-PBMC		· · · · · · · · · · · · · · · · · · ·				. : 480
CM4-32 :	· · · · · · · · · · · · · · · · · · ·					. : 480
CM4-Bob :	· · · · · · · · · · · · · · · · · · ·		•••••	•••••	• • • • • • • • • • • • • • • • • • • •	. : 480
	m41					
	* 500 *	- 520 *	540	* 560	* 580 * 60	0
CM4-P1 :	ELYKYKVVQIEPLGVAPTKAKRRVVEREKRAIGFGA	MFLGFLGAAGSTMGAASV	TLTVQARQLLSGI	QQQNNLLRAIEAQQHMLKL	TVWGIKQLQARVLAVEKYLKDQQLLGIWGCS	K : 600
CM4-P2 :	• •••••••		• • • • • • • • • • • • • • • •			. : 600
CM4-PBMC		• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • •			. : 600
CM4-Bob		· · · · · · · · · · · · · · · · · · ·				. : 600
CN4 . D1	* 620 *	640 *	660	* 680	* 700 * 72	0t
CM4-P1 :	STOLING HADDROND THANKINA MEREIDA	·····				. : 720
CM4-PBMC :						. : 720
CM4-32 :	• • • • • • • • • • • • • • • • • • • •					. : 720
CM4-Bob :	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • •			. : 720
	* 740 *	760 *	780	* 800	* 820 * 84	0
CM4-P1 :	HHQRESPDRPGRIEEGDGEQDRDRSIRLVSGFLALA	WDDLRSLCLFSYHRLRDS	ILIVARILELLGH	GWEILKYLWSLLQYWSQEL	KNSAINLFNTLAIAVAEGTDRIIEAILRICR/	I : 840
CM4-P2 :						. : 840
CM4-32						. : 840
CM4-Bob :						. : 840
(M4-D1	* DNTDTDTDC/1.02221. 956					
CM4-P2 :						
CM4-PBMC :	: 856					
CM4-32 :						
CW4-ROD :						
R						
D						
gp120					100 I I I I I I I I I I I I I I I I I I	
CM9-PBMC :	* 20 * 40 MRVREILRNYOOWWIWSILGFWMICNVVGNLWVTVYYGVP	* 54 VWKEAKTTLFCASDAKAYE	* KEVHNVWATHACVP1	80 * DPNPOEMHLENVTENFNMWKNI	100 * 120 MVDOMHEDIISLWDOSLKPCVKLTPLCVTLECT	. : 130
CM9-X4 :						: 130
CM9-Bob : CM9-R5 :		••••••	• • • • • • • • • • • • • • • • •	••••••	K.G	: 130
CM9-CXCR6						
cmp - cherer						: 130
CM9-R3 :					К.G	: 130
CM9-R3 :	v2					: 130
CM9-R3 :	V2 140 * 160	* 180	* 200	* 220		: 130 : 130 : 130
CM9-R3 : CM9-PBMC : CM9-X4 :	V2 140 • 160 ATFN - STTHNAATINDT LAGENKING SAWT TELEBORKKE	* 180 YALFYRLDIVPLGGNSSKG	* 200 NASKYRLINCNSSTI	 220 TQACPKVSFDPIPIHYCAPAGY 	.K.G K.G 240 ALLKCNNKTFNGTGPCNNVSTVQCTHGIKPVVS	: 130 : 130 : 130 : 259 : 259
CM9-PBMC : CM9-X4 : CM9-Bob :	V2 140 • 160 ATEN-STEIBRATINDTIAGEMKNCSENVTIELRORKKKE	★ 180 YALFYRLDIVPLGGNSSKG	* 200 NASKYRLINCNSSTI	• 220 TQACPKVSFDPIPIHYCAPAG	K.G. K.G MILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVS	: 130 : 130 : 130 : 259 : 259 : 259
CM9-PBMC : CM9-X4 : CM9-R5 : CM9-R5 : CM9-R5 :	V2 140 1 160 NTPN-STTHRMATINDTLAGENENCSPNVTTELERDREXCE 	★ 180 YALFYRLDIVPLGGNSSKG	◆ 200 NASKYRLINCNSSTI	• 220 TQACPKVSFDPIPIHYCAPAGY	K G K G Z40 ZALLECNNKTFNGTGPCNNVSTVQCTHGIKPVVS	130 130 130 130 260 259 259 259 259 260 260
CM9-PBMC : CM9-PBMC : CM9-X4 : CM9-Bob : CM9-R5 : CM9-CXCR6 : CM9-R3 :	V2 140 • 160 XTFN-STHUNNTYNTIAGEMEKESFNYTTELEDEKKKE 	 180 YALFYRLDIVPLGGNSSKG 	◆ 200 NASKYRLINCNSSTI	• 220 Голсркубррірівусараці	K.G .K.G ALLKCNNKTPHOTOPCHNVSTVQCTHGIKPVVS	260 259 259 259 259 259 259 260 260 260 260
CM9-PBMC : CM9-PBMC : CM9-X4 : CM9-Bob : CM9-R5 : CM9-R5 : CM9-R5 : CM9-R3 :	V2 140 160 ATFN-STHENATINDT AGENGKICS FRVTTELEDERKKE 	* 180 YALFYRIDIVPLOGNSSKC	• 200 NASKYRLINCNSSTI	* 220 TQACPEVSFDPIPIHYCAPAG		130 130 130 130 130 130 130 130
CM9-PBMC : CM9-PBMC : CM9-X4 : CM9-Bob : CM9-R5 : CM9-R3 :	V2 140 120 ATFN-STINDMINDIAGENER/CSFN/UTELADEX/KE N.Y.S.KT. N.Y.S.KT. N.Y.S.KT. V3 280 3	180 YALFYRLDIVPLGGNSSKG	* 200 NASKYRLINCNSSTI	220 TQACPRVSFPPIPIHYCAPAG 340	240 ALLECHNICTPHOTOPCINIVSTVQCTHOLEPVVS 360 - 360	130 130 130 130 130 130 130 130
CM9-PBMC : CM9-PBMC : CM9-R5 : CM9-R5 : CM9-R5 : CM9-R3 : CM9-PBMC :	V2 140 + 160 ATPM-STINNATINGTIGENCKCSPNTTELEDORKKE 	180 VALFYRLDIVFLGGMSEKG 3 00 00 REGNTIKRIRIGPRYAFY	* 200 NASKYRLINCNSSTI 320 KKETIIGDIRQAHCN	220 годсржубррірінсардо 340 ібеекмитіодуускі кенрі		: 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 260 : 260 : 260
CM9-PBMC : CM9-PBMC : CM9-PBMC : CM9-R5 : CM9-R5 : CM9-R3 : CM9-R3 : CM9-PBMC : CM9-PBMC : CM9-PBMC :	V2 140 160 ATFN-STIMMATINGTAGEMENCSFAVTELLDEKKE N.Y.S	• 180 YALFYRLDYVPLGONSSKG 00 RFGNNTIKRIRIGDRYAFY	200 NASKYRLINCNSSTI 320 AKETIIGDIRQAHCN	220 ГОЛСРЕКУБРОР ГР ПИТСАРАСІ 1906 ГРИТОРИ ГРИТИСАРАСІ 1906 ГИЛИСТИСАРИСТИКИ 1906 ГИЛИСТИСАРИСТИКИ 1906 ГИЛИСТИСАРИ	К. 6 	: 130 : 130 : 130 : 259 : 259 : 259 : 260 : 260 : 260 : 260 : 260 : 389 : 389 : 389
CM9-R3 : CM9-PBMC : CM9-X4 : CM9-R5 : CM9-R5 : CM9-R3 : CM9-R3 : CM9-PBMC : CM9-PBMC : CM9-PBMC : CM9-R3 :	V2 140 160 ATFN-STINDMITMOTIAGENERKOSFWYTTELADERKKE N.Y.S.KT. N.Y.S.KT. N.Y.S.KT. V: 280 3 QLLINGSLABEBI I INSENLIDINKTI I VELINBSVEIVCA	 180 YALEYELDIVELGONSSKO 00 RFGNNTIKEREGPRAFY , R, G. 	200 KARKYRLINCNSSTI 320 KRETIIGDIRQAHCM	220 TQACPEVSFDPIPIHYCAPAG 1900 1900 1900 1900 1900 1900 1900 190	К. 6 . К. 6 /ALLKCHNKEPHOTOPCHNVSTVQCTHOLKPVVS /ALLKCHNKEPHOTOPCHNVSTVQCTHOLKPVVS // 360 / 380 // 1115/2016/1115/2016/2016/2016/2016/2016/2016/2016/2016	: 130 : 130 : 130 : 130 : 259 : 260 : 259 : 259 : 259 : 260 : 260
CM9-R3 : CM9-PBMC : CM9-X4 : CM9-Bob : CM9-R5 : CM9-R5 : CM9-R3 : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-R3 : CM9-R3 :	V2 140 160 XTPN-STTHENATINDTIAGENCUSPANTIELEDREKKE 	 180 ALFYFLDIVPLGGNSEKG 00 COMPONTIKRIRIGPRVAFI R G R G R G R G R 	200 NASKYPLINCNSSTI 320 NKETIIGDIRQAHCM	220 TQACPEVSEPPI DIRYCAPAG 340 ISBEKWNKTLQQVGKKLKEHFI 6 6 6	X. G X. G ZALUCCHNYTFHOTOCOLNYSTVOCTHOLKSYVS ZALUCCHNYTFHOTOCOLNYSTVOCTHOLKSYVS ZALUCCHNYTFHOTOCOLNYSTVOCTHOLKSYVS ZALUCCHNYTFHOTOCOLNYSTVOCTHOLKSYVS X X X X X X X X X X X X X X X X X X X	: 130 : 130 : 130 : 130 : 130 : 259 : 260 : 290 : 290
CM9-R3 : CM9-R3 : CM9-R4 : CM9-R5 : CM9-R5 : CM9-R3 : CM9-R3 : CM9-R3 : CM9-R3 : CM9-R3 : CM9-R3 : CM9-R3 :	V2 140 160 ATFM-STHENATINGTAGEREKICSFAVITELDERKKE N.Y.S	• 180 *ALEYRLDYVPLGANSSKG 00 00 RFGNTIKRIRIGPRVAFY R. G. R. G. R. G.	200 NASKYRLINGNSTI 320 AKETIIGDIRQAHCM A. A.	220 ГОЛСРЕКУБРОР IP INYCAPAG 340 I SEEKMINTLQQVGEKLKENFI 	240 ALLECHNETFNOTOCINVSTVOCTHOLEPVS 360 360 360 380 V4	: 130 : 130 : 130 : 130 : 259 : 259 : 259 : 260 : 260 : 260 : 389 : 389 : 390 : 390 : 390
CM9-R3 : CM9-PBMC : CM9-PbMC : CM9-R5 : CM9-R5 : CM9-R5 : CM9-R3 : CM9-R3 : CM9-R3 : CM9-R5 : CM9-R5 : CM9-R5 : CM9-R3 :	V2 140 160 ATFN-STINBNATNOTIAGENERKOSENVITUELADERKER N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. V. 280 3 QLLINGSLABEDI I INSENLTINKETI IVILIABEVPIVOA	• 180 YALEYELD IVPLGONSSEG 00 RFGNYTKER RIGPRYAFY RG	200 MARYELINCHSST 320 MARTIIGDIRQAHCM A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.	220 TQACPEVSFDPIPIHYCAPAG 340 ISBEKKNNTLQQVGKKLKBHPI 	К. 6 	: 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 260 : 260 : 260 : 389 : 389 : 390 : 390
CR9-P3X : CR9-P3RC : CR9-P3RC : CR9-P3RC : CR9-P3RC : CR9-P3RC : CR9-P3RC : CR9-P3RC : CR9-R3 : CR9-R3 : CR9-R3 : CR9-R3 : CR9-R3 : CR9-R3 : CR9-R3 :	V2 140 1 160 ATEM-STINNATADDIAGENKISENVITELRERKKE 	180 1	• 200 MARYYELINCHSST 320 MARTIIGJIRJAHCS A. A. A. A. A. A. A. A. A. A. A. A. A.	• 220 TQACPEVSFPPIPIHYCAPAG 340 SBEEKWNTLQQVGKLIEHPI 	К. 6 	: 130 : 130 : 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 260 : 260 : 260 : 389 : 389 : 389 : 390 : 390 : 390 : 390 : 390 : 390 : 390 : 390
CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-Bob C CH9-Bob C CH9-R3 : CH9-PBMC : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 :	V2 140 100 ATFM-STIMMATINDT AGENERICS FAVITE LEDERKKE N. Y.S	180 180 100 1	AREYNLINCNSST AREYNLINCNSST 320 ARETIIGDIRQAHCM A. A. A. A. A. A. A. A. A. A. A. A. A.	220 TQACPEVSFPPIPIHYCAPAG 340 ISEEKMINTLQQVGKKLKEHFI 	к. с к. с	: 130 : 130 : 130 : 130 : 130 : 130 : 130 : 259 : 250 : 260 : 389 : 390 : 519 : 519 : 519 : 519 : 519
CM9-R3 : CM9-R3 : CM9-R4 : CM9-R4 : CM9-R4 : CM9-R3 : CM1-CM1-CM1-CM1-CM1-CM1-CM1-CM1-CM1-CM1-	V2 140 • 160 ATFN-STININATINOTIAGENERICSEN N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. V3 QLLINGSLABEETI INSENITONYKTITVIINESPPIVCA 400 • 420 LFNRPHOTESNINATTESNINATITUQCIEGIIINMQEV	• 180 * 180 * ALEYRED UPLGONSSKG 00 RCGNTIKEREGPEARY 	200 MARTYELINCHSST 320 MARTYELIN	220 TQACPEVSFDPIPIHYCAPAG 340 58EEKNNTJQQVGKKJKEHFJ 66. 66. 60. 80. 80. 80. 80. 80. 80. 80. 80. 80. 8	К. 6 . К. 6 . К. 9 	: 130 : 130 : 130 : 130 : 130 : 130 : 130 : 259 : 250 : 260 : 389 : 389 : 390 : 390 : 390 : 519 : 520 : 519 : 520 : 519 : 519 : 520 :
CM9-PJBMC : CM9-PJBMC : CM9-PJBMC : CM9-R3 : CM9-R5 : CM9-R3 : CM9-PJBMC : CM9-R3 : CM9-CM9-CM9- CM9-CM9-CM9-CM9-CM9-CM9-CM9-CM9-CM9-CM9-	V2 140 10 150 ATTM-STITHONTITOTIAGEMENCSPNYTELROPAKKE 	• 180 VALEYTELD IVPLCONSERCE 00 8 RFGNNTIERTER GPFYAPY 	* 200 MARYHLINCHSST 320 * AKETIIGJIRJAHCN * A X X X X X X X X X X X X X X X X X X	• 220 TQACPEVSFDPIPIHYCAPAG 340 58EEKWNTLQQVGKLIKHFI 66. 67. 68. 69. 60. 60. 60. 60. 60. 60. 60. 60. 60. 60	К. 6 	: 130 : 130 : 130 : 130 : 130 : 130 : 259 : 260 : 259 : 260 : 260 : 389 : 389 : 389 : 389 : 390 : 390 : 390 : 519 : 519 : 519 : 520
CH9-R3 C CH9-PBAC : CH9-PBAC : CH9-R0b : CH9-R0b : CH9-PBAC : CH9-PBAC : CH9-PBAC : CH9-PBAC : CH9-R5	V2 140 160 ATFM-STIMMATINDTIAGERENCEFWYTELDERKKE N. Y.S	180 1	AREYHLINNSST AREYHLINNSST 320 ARETIIGDIRQAHCM A. A. A. A. A. A. A. A. A. A. A. A. A.	220 TQACPEVSFPPIPIHYCAPAG 1886KMNKTLQQVGKKLKEHF 1886KMNKTLQQVGKKLKEHF 6 6 6 6 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	к. к. с 	: 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 260 : 260 : 389 : 390 : 390 : 519 : 519 : 519 : 519 : 519 : 519 : 519 : 519 : 520 : 520
CH9-R3 :: CH9-PBAC :: CH9-PBAC :: CH9-R6bb : CH9-R3 :: CH9-CXCR6 : CH9-R3 :: CH9-PBAC :: CH9-R3 :: CH9-PBAC :: CH9-R3 :: CH9-R3 :: CH9-R3 :: CH9-R3 :: CH9-CXCR6 : CH9-R3 :: CH9-CXCR6 : CH9-R3 ::	V2 140 • 160 ATFM-STIMBNATNOTIAGENERKOSPHERITILDERKER N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. V3 QLLINGSLABEDI I HSINI, TUNKTI 1 VILIABEPPI VCA 400 • 420 LFMRPHOTESNON/TTESNONTI TLQCRIRGI INMAQEV	• 180 XALEYELD VELGONSSEG 00 RCONTINETE GPRXAPY 	200 MARYHLINCNSST 320 KKTTIGDIRQAHCN X X X X X X X X X X X X X X X X X X X	220 TQACPEVSFPPIPIHYCAPAG 340 340 340 340 340 340 340 340 340 340	К. 6 К. 6	: 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 259 : 259 : 259 : 260 : 260 : 260 : 389 : 389 : 390 : 390 : 390 : 519 : 519 : 520 : 520 : 520
CH9-R3 C CH9-R3 C CH9-PBMC I CH9-PBMC I CH9-PBMC I CH9-PBMC I CH9-PBMC I CH9-PBMC I CH9-R3 I CH9-PBMC I CH9-R3 I CH9-PBMC I CH9-R3 I CH9-R3 I CH9-R3 I CH9-PBMC I CH9-R3 I CH9-R3 I CH9-PBMC I CH9-R3 I CH9-PBMC I CH9-R3 I CH9-R3 I CH9-R3 I CH9-PBMC I CH9-R3 I CH	V2 140 160 ATEN-STITUENATUDI LAGENENCE FUNTELERBEKKER N. Y.S. KT. N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. QLLINGS LABEET I INSENI/TONVET I VILINESUP IV CA 400 420 LEMREPROTEENNENTT TLOCRITICUENTINGEU VELOFICIALASTIMUM STATUTOTEDULISOTUDOCONILIS	180 XALEYRLD IVPLGANSSKA XALEYRLD	200 MARYPELININSST 320 AKETIIGDIRQAHCM A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.	220 TQACPEVSFPPIPIEVCAPAG 340 58EEKKNNTJQQVGKKLKEHFI 600 600 600 600	К. 6 К. 6	: 130 : 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 259 : 259 : 260 : 260 : 260 : 260 : 389 : 390 : 390 : 390 : 390 : 519 : 519 : 519 : 520 : 389 : 389 : 389 : 390 : 390 : 519 : 519 : 519 : 519 : 519 : 519 : 519 : 520 :
CH9-R3 : CH9-PBNC : CH9-R3 : CH9-PBNC : CH9-R3 : CH9-PBNC : CH9-R3 : CH9-PBNC : CH9-R3 : CH9-R3 : CH9-PBNC : CH9-R3 : CH9-R3 : CH9-PBNC : CH9-R3 : CH9-CH9-CH9-CH9-CH9-CH9-CH9-CH9-CH9-CH9-	V2 140 100 ATFM-STHMANTATUTAGENERKISHVITELDERKKE N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. 280 3 QLLLNGSLABEELI INSENTITUVETI IVELNESVPIVCA 400 420 LFMRPHOTESNENTTENSNETTITUQCELESI INSMOSP VFLOFLGAAGSTMGAASTALTVQTEQLISGI VQQQSLLE	* 180 *ALFYRLDTVPLGANSSKG 00 RFGNNTIKRIRIGPEVAFT 	ARETHLINCHSST ARETHLINCHSST 320 ARETIIGDIRQANC A. A. A. A. A. A. A. A. A. A.	220 TQACPEVSFPPIPIHYCAPAG 1940 19	К. 6 	: 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 259 : 259 : 259 : 260 : 260 : 260 : 260 : 260 : 259 : 389 : 390 : 390 : 390 : 390 : 390 : 390 : 259 : 519 : 519 : 519 : 520 : 549 : 549 : 549 : 549 : 549 : 549 : 549 : 549 : 389 : 389 : 390 : 390 : 390 : 519 : 519 : 519 : 519 : 519 : 519 : 519 : 519 : 520 : 520 : 520 : 520 : 520 : 520 : 520 : 520 : 520 : 549 : 540 : 549 : 549 : 540 : 549 : 540 : 549 : 540 : 5
CH9-R3 : CH9-PBMC : CH9-PBMC : CH9-R6bb : CH9-R5 : CH9-R5 : CH9-R3 : CH9-PBMC : CH9-PBMC : CH9-R3	V2 140 • 160 ATFM-STIMBARTNOTIAGENERKOSFWITILDDEKKE N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. VI QLLINGSLABEDI INSINITING VI • 280 • 3 QLLINGSLABEDI INSINITING VI • 280 • 3 VI QLLINGSLABEDI INSINITING VI • 280 • 3 VI • 280 • 3 VI • 280 • 3 • 540 • 420 LFMRPHOTESNINGTESNINGTING VI VELOFLOADOSTMOAASIALTVQTRQLLSGTVQQQSNLR	180 XALEYELDIVELGONSSEG ALLYELDIVELGONSSEG Reconstructors Reconstructors Reconstructors ALEROGEBILQLIVESIKGL	200 MARYTELINCNSST 320 AKATILGDIRQAHCM AKATILGDIRQAHCM A A A A A A A A A A A A A A A A A A A	220 COACPEVSFPPIPIPIPICAPAG 340 340 340 340 340 340 340 340	К. 6 К. 6	1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 260 1 260 1 260 1 389 1 389 1 390 1 519 1 519 1 519 1 520 1 520 1 520 1 519 1 520 1
CH9-R3 : CH9-R3 : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH	V2 140 160 ATEM-STITIONATINOTIAGEMENCSENVITIELROBEKEE N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. 250 3 QLLINGSLABEETITISENLIDINETITUELROBEVETUCA 250 3 QLLINGSLABEETITISENLIDINETITUELROBEVETUCA 100 420 420 LENREPROTEENNINTTEENNINTITUCEREDIINMOGEV 100 400 420 LENREPROTEENNINTTEENNINTITUCEREDIINMOGEV 100 400 5 5 VELOFLEANASTMIAASIALTVQTEQLLSOTVQQOSILLE	180 XALEYELD IVPLOADS SKG ALEYELD IVPLOADS SKG ALEYELD IVPLOADS SKG ALEXANDER SKG	200 MARYPELINCNSST 320 AKETIIGDIRQAHCN A. A. A. X. Y5 460 TOLLITROGENTI S80 DTRVLSIERVLEDQC	220 COACPEVSEPPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPE		: 130 : 130 : 130 : 130 : 130 : 130 : 130 : 259 : 259 : 259 : 250 : 389 : 389 : 390 : 519 : 519 : 519 : 520 : 520 : 520 : 649 : 649 : 649 : 649 : 649 : 649 : 650
CH9-R3 : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-R3 :	V2 140 100 ATFM-STIMMATATOTIAGERKICSFWTTELDERKKE N. Y.SKT. N. Y.SKT. N. Y.SKT. 	* 180 *ALPYRLDIVPLGANSSKG 00 RFGSNTIKRIEGPEVAFY R. G. G. G. G. G. 	ARETHLINCHSST	220 TQACPEVSFPPIPIHYCAPAG 1940 19	К. 6 	1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 390 1 390 1 519 1 519 1 519 1 519 1 519 1 519 1 519 1 519 1 559 1 550 1
CM9-R3 : CM9-R3 : CM9-PBAC : CM9-R4 : CM9-R5 : CM9-R5 : CM9-R3 : CM9-PBMC : CM9-PBMC : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R5 : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-PBMC : CM9-R3 : CM9-R3 : CM9-R3 : CM9-CXCR6 : CM9-R3 : CM9-R	V2 140 • 160 ATFM-STICHENATIOTIAGENERKSEFFUELDERKEE N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. 280 • 3 QLLINGSLABEETI HESENITENKETI VELKBEPPIVCA 400 • 420 LFMREMOTEENNINGTEENNENTITLQCRIRQIINMAQEV 540 • 540 • 550 VELOFLOAMOSTMOMASTALTVQTRQLLSGTVQQQSNLR	180 XALEYRED UVPLGONSSKG ALLYRED UVPLGONSSKG ReGNTIKEREGPRAY R	• 200 MARYNELINNSST 320 • AKATILGIRQAHCM X X X X X X X X X X X X X X X X X X X	• 220 COACPEVERPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP	К. 6 	1 130 1 130 1 130 60 60 1 259 1 260 1 389 1 399 1 519 1 519 1 520 1 550 1
CH9-R3 : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-PBMC : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-PBMC : CH9-R3 : C	V2 140 * 160 ATFN-STINENTINOTIAGENERICSFVTTELBOREKER N.Y.S. KT. N.Y.S. KT. Y.S. KT. VI 280 * 3 QLLINGSLAREETI INSENITONYETI VELMBEVEVUCA UNDERSTINENTITESENINTTITUCERED INSEGUE 400 * 420 LEVREPROTESENINTTESENINTTITUCERED INSEGUE VELOFLGANGSTMINASTALTVOTEDLLSOTVQQQSILLE 660 * 680	180 XLEYRLDIVPLGONSSKG ALLYRLDIVPLGONSSKG ALLYRLDIVPLGONSSKG Reconstruction Reconstruction ALLO ALLO ALLO ALL	200 AARTYELINCHSST 200 AARTYELINCHSST 320 4 4 5 4 5 4 5 5 6 7 720	220 COACPEVESPOPTPIHYCAPAGI 340 138840 138840 138840 138840 138840 138840 138840 13		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
CH9-R3 : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH9-CH9-CH9-CH9 : CH9-R3 : C	V2 140 160 ATFM-STHMANTATUTACHERKICSFWTELEDERKRE N. Y. S. KT. N. Y. S. KT. N. Y. S. KT. VI 280 VI QLLLNGSLAREELI I RESENT.TUNVET I IVEL.RESVFVCA VI QLLLNGSLAREELI I RESENT.TUNVET I IVEL.RESVFVCA 400 420 LFNRPROTESNINGTEENINT.TUQCETEGLI INMOGEN VFLOFLGAAGSTMGAASIALITQTEGLISGI VQQQSHLEE VFLOFLGAAGSTMGAASIALITQTEGLISGI VQQQSHLEE 550 580 580	180 1	ARETHLINCHSST	220 TQACPEVSFPPIPIHYCAPAG 340 188844 18884 18884 188844 188844 188844 188844 188844 18884	К. 6 	1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 259 1 260 1 389 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 519 1 519 1 529 1 390 1 390 1 519 1 519 1 529 1 390 1 390 1 390 1 519 1 519 1 519 1 519 1 519 1 529 1 390 1 390 1 390 1 519 1 550 1
CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R4 : CH9-R3 : CH9-R3 : <tr< th=""><th>V2 140 160 ATFM-STICHENATIOTIAGENERICSFWITTELDDEKKE N.Y.S.KT. N.Y.S.KT. 280 3 QLLINGSLABEDII INSINITINKTII VELIABSVPIVCA 280 43 QLLINGSLABEDII INSINITINKTII VELIABSVPIVCA 400 420 LFMRENGTESNINKTIESININTITUCCRIRQII INMQEV 400 540 LFMRENGTESNINKTIESININTITUCCRIRQII NIMQEV 540 550 VFLGFLGANGSTMGAASIALTVQTEQLLSGIVQQQSNLLE 540 580 ESQNQQENIKKELLELDEMKINIMENTDI TOMINTIKIFI</th><th>180 XLLYPED UVPLGONSSEG ALLYPED UVPLGONSSEG RCONTINE GPRATY R</th><th>200 MARYTELNENST 320 AKATTELNENST 320 AKATTELINENST 320 AKATTELINENST 450 TOLLITEDGOEKNT 580 278VLSIERVLADQO 278VLSIERVLADQO</th><th>220 COACPEVESPEPIPINYCAPAG 340 340 340 SBEEKNNTLQQVGKKLKHFI 0 0 0 0 0 0 0 0 0 0 0 0 0</th><th>К. 6 К. 7 К. 7</th><th>1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 390 1 390 1 390 1 390 1 390 1 519 1 520 1 539 1 539 1</th></tr<>	V2 140 160 ATFM-STICHENATIOTIAGENERICSFWITTELDDEKKE N.Y.S.KT. N.Y.S.KT. 280 3 QLLINGSLABEDII INSINITINKTII VELIABSVPIVCA 280 43 QLLINGSLABEDII INSINITINKTII VELIABSVPIVCA 400 420 LFMRENGTESNINKTIESININTITUCCRIRQII INMQEV 400 540 LFMRENGTESNINKTIESININTITUCCRIRQII NIMQEV 540 550 VFLGFLGANGSTMGAASIALTVQTEQLLSGIVQQQSNLLE 540 580 ESQNQQENIKKELLELDEMKINIMENTDI TOMINTIKIFI	180 XLLYPED UVPLGONSSEG ALLYPED UVPLGONSSEG RCONTINE GPRATY R	200 MARYTELNENST 320 AKATTELNENST 320 AKATTELINENST 320 AKATTELINENST 450 TOLLITEDGOEKNT 580 278VLSIERVLADQO 278VLSIERVLADQO	220 COACPEVESPEPIPINYCAPAG 340 340 340 SBEEKNNTLQQVGKKLKHFI 0 0 0 0 0 0 0 0 0 0 0 0 0	К. 6 К. 7 К. 7	1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 390 1 390 1 390 1 390 1 390 1 519 1 520 1 539 1
CH9-R3 : CH9-R3 : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-PENC : CH9-R3 : CH9-R3 : CH9-PENC : CH9-R3 : CH9-R3 : CH9-R3 : CH9-PENC : CH9-R3 : CH9-	V2 140 160 ATFN-STINENTINOTIAGENERICSFWITTELBORKER N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. 280 3 QLLINGSLABESI I INSENITONYET I VELMBEVPIVCA QLLINGSLABESI I INSENITONYET I VELMBEVPIVCA LENRPHOTEENENTTEENENTTITUCELLEUT 400 420 LENRPHOTEENENTTEENENTTITUCELLEUT 400 500 500 LENRPHOTEENENTTEENENTTITUCELLEUT 400 500 500 ESQNQQEENEKELLEUDSHENINSHFD I TOMHYIKIFIM 	180 XLEYRLDIVPLGONSSKG ALLYRLDIVPLGONSSKG 00 RCGNTIKEIEIGPEVAEY	200 MARYPELNCNSST 320 MARYPELNCNSST 320 MARYPELIGDIRQAHCM A A A A A A A A A A A A A A A A A A A	220 COACCPEVOSPOPIPIPIYCAPAGI 340 ISBEKWANTLOQVGKKLKBHFI 		1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 255 1 389 1 390 1 519 1 519 1 552 1 555 1
CH9-R3 : CH9-R3 : CH9-PENC : CH9-R3 : CH9-R5 : CH9-R5 : CH9-R5 : CH9-R5 : CH9-R5 : CH9-R5 : CH9-R3	V2 140 • 160 ATFM-STHENATINDIXAGENERGENEVITILDERKEE 	180 1	ARETHLINCHST	220 TQACPEVSFPPIPIHYCAPAG 340 188844 18884 18884 188844 188844 188844 188844 188844 18884	К. 6 	1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 259 1 260 1 259 1 389 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 519 1 519 1 519 1 529 1 519 1 519 1 529 1 519 1 519 1 519 1 529 1 519 1 529 1 390 1
CH9-R3 : CH9-R3 : CH9-R3 : CH9-R3 : CH9-R4 : CH9-R3 : CH9-R3 : <tr< th=""><th>V2 140 • 160 ATFM-STICHENATIOTIAGENERICSENTILLIDERENE N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. 280 • 3 QLLINGSIABEEIIINSINITATIVIIINESPEVIVA 100 • 420 LFMRENGTESNINGTTESNINITIUQCEIISQIINMAQEV 540 • 550 VELGELGAAGSTMGAASIALTVQTEQLLSGIVQQQSHLE 540 • 580 ESQNQQEENERLELEDGMENIMEMEDITALISTIKIETEM</th><th>• 180 * ALLYPELD VYPLGONSSKA * ALLYPELD VYPLGONSSKA * CO * CO</th><th>200 MARYTELNENSST 320 AKKTILDIROMCN A A A A A A A A A A A A A A A A A A A</th><th>220 TQACPEVEPPIPIPIYCAPAG 340 340 340 SBEEKNNTLQQVGKKLKHPI 0 0 0 0 0 0 0 0 0 0 0 0 0</th><th>К. 6 </th><th>1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 519 1 520 1 5779 1 779 1 778 1 778 1 778</th></tr<>	V2 140 • 160 ATFM-STICHENATIOTIAGENERICSENTILLIDERENE N.Y.S. KT. N.Y.S. KT. N.Y.S. KT. 280 • 3 QLLINGSIABEEIIINSINITATIVIIINESPEVIVA 100 • 420 LFMRENGTESNINGTTESNINITIUQCEIISQIINMAQEV 540 • 550 VELGELGAAGSTMGAASIALTVQTEQLLSGIVQQQSHLE 540 • 580 ESQNQQEENERLELEDGMENIMEMEDITALISTIKIETEM	• 180 * ALLYPELD VYPLGONSSKA * ALLYPELD VYPLGONSSKA * CO * CO	200 MARYTELNENSST 320 AKKTILDIROMCN A A A A A A A A A A A A A A A A A A A	220 TQACPEVEPPIPIPIYCAPAG 340 340 340 SBEEKNNTLQQVGKKLKHPI 0 0 0 0 0 0 0 0 0 0 0 0 0	К. 6 	1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 390 1 519 1 520 1 5779 1 779 1 778 1 778 1 778
CH9-R3 : CH9-R3 : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH	V2 140 160 AFFH-STHENN THOT LABERENCE FINISHER TELEBORKER N. Y. S. KT. N. Y. S. KT. N. Y. S. KT. N. Y. S. KT. Y. 280 '''. QLLLNOST.AREET I INSENI-TONYKT I VILINBEVPLYCA Y''. 400 420 LFNRPHOTESNINGTTENNISTITUQUELLSOTVQQOSILE '''. VPLOFLGAAGSTMAASTALTVYTROLLSOTVQQOSILE 540	• 180 * 180 * ALEY TELD UPE GONS SKG * ALEO * GONTIE REGPENTARY * 440 GOMMY APP IKGNICTSNI * 440 GOMMY APP IKGNICTSNI * 440 * 440 GOMMY APP IKGNICTSNI * 440 * 440 GOMMY APP IKGNICTSNI * 440 * 700 * 700	* 200 MARTYLLINCNSST 320 A.A. A. A. A. A. A. A. A. A.	220 COACCPEVESPOPTPTITYCAPAG COACCPEVESPOPTPTITYCAPAG SEEKWANTLOQVGKKLKENFF		1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 259 1 260 1 259 1 260 1 389 1 390 1 390 1 519 1 519 1 550 1 570 1
CH9-R3 : CH9-R3 : CH9-PENC : CH9-R5	V2 140 • 160 ATFM- STHEMA THOT LAGENERICS FAUT ELEDERKEE 	180 1	ARETHLINCHSST ARETHLINCHSST 320 ARETIIGDIRQAHCM A. A. A. A. A. A. A. A. A. A.	220 70ACPEV95PP1P1HYCAPAG 70ACPEV95PP1P1HYCAPAG 1586444 1586444 1586444 158644 158644 158644 158644 158644 158644 158644 15864 15864 15864 15864 1586 1586 1586 1586 1586 1586 1586 1586 1586 1586 158 1	К. 6 	1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 260 1 390 1
CH9-R3 : CH9-R4 : <th>V2 140 160 ATFM-ST.HHRNTNDTIAGENERGEFWITELDDEKKE N.Y.S.KT. N.Y.S.KT. 280 3 QLLINGSIABEEII INSENITINKTIIVELMBEPFVCA 280 40 280 3 QLLINGSIABEEII HSENITINKTIIVELMBEPFVCA 400 420 LFMRFHOTESHINGTTESHINITIUQCEIISQIINMAQEV 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 100 5 10</th> <th>180 18 180 18 180 18 180 18 1</th> <th>200 AREYTELNENSET 200 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELSTOR AND A AREYTELSTOR AND A AREYTELSTOR AND A</th> <th>220 TQACPEVSFPPIPINYCAPAG 340 340 340 340 340 340 340 34</th> <th>К. 6 </th> <th>1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 399 1 592 1 592 1</th>	V2 140 160 ATFM-ST.HHRNTNDTIAGENERGEFWITELDDEKKE N.Y.S.KT. N.Y.S.KT. 280 3 QLLINGSIABEEII INSENITINKTIIVELMBEPFVCA 280 40 280 3 QLLINGSIABEEII HSENITINKTIIVELMBEPFVCA 400 420 LFMRFHOTESHINGTTESHINITIUQCEIISQIINMAQEV 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 VFLGFLGAAGSTMOAASIALTVQTEQLLSGIVQQQSHLE 540 5 100 5 10	180 18 180 18 180 18 180 18 1	200 AREYTELNENSET 200 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELNENSET 320 AREYTELSTOR AND A AREYTELSTOR AND A AREYTELSTOR AND A	220 TQACPEVSFPPIPINYCAPAG 340 340 340 340 340 340 340 34	К. 6 	1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 260 1 389 1 399 1 592 1
CH9-R3 : CH9-R3 : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-PENC : CH9-R3 : CH9-PENC : CH9-R3 : CH	V2 140 160 ATFN-STINENTINDI LAGENERICSFWITTELBORKER N. Y.S. KT. N. Y.S. KT. N. Y.S. KT. VI 280 13 QLLINGSLAREELI INSENITOWERTI VELINBEUPUVCA 400 4 420 LFNRPHOTESNINGTTESNINTITUQUINGLISH VELOFLGAAGSTMAASIALTUQTROLLSOIVQQQSHLE 0 0 0 0 0 0 0 0 0 0 0 0 0	180 1	• 200 •ARETYLLINCHSST 320 •ARETIIGDIROANC • * * * * * * * * * * * * * * * * * *	220 COACCPEVESPOPTPIHYCAPAG COACCPEVESPOPTPIHYCAPAG SA40		1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 130 1 259 1 259 1 259 1 259 1 259 1 259 1 260 1 260 1 260 1 389 1 389 1 390 1 390 1 519 1 519 1 559 1 550 1 577 1 577 1 779 1 7780 1 780



Fig. 2. Inhibition of CM9 in $\Delta 32/\Delta 32$ CCR5 PBMC. (A) Growth curve of CM9 in the presence of AMD3100, vMIP-1, I309, eotaxin or without inhibitors. (B) CM9 in the presence of AMD3100 alone or in combination with vMIP-1, I309 or eotaxin or no inhibitors. RT activity was used to measure viral replication levels.

(Fig. 3). CXCL16 is the natural ligand for CXCR6. None of these inhibitors had any effect on CM4 replication except vMIP-1, which caused a delay. Hence, CM4 is using a coreceptor other than CCR5, CXCR4, CCR8 or CXCR6 to productively infect PBMC. Its identity is still unclear, but it may be a vMIP-1 receptor.

Discussion

The identification of HIV-1 isolates able to use coreceptors other than CCR5 and CXCR4 on primary cells is rare (Lee et al., 2000; Willey et al., 2003; Zhang et al., 2000). While the significance of alternate coreceptor usage is



Fig. 3. Replication of CM4 in $\Delta 32/\Delta 32$ CCR5 PBMC in the presence of AMD3100, vMIP1, I309, eotaxin, CXCL16 or without inhibitors. RT activity was used to measure viral replication levels.

uncertain, the possibility that HIV-1 can expand its cellular host range through the use of alternate coreceptors remains a theoretical possibility especially for HIV-1 subtype C where CXCR4 is rare. Here, we report on how two isolates, CM4 and CM9, can use alternate coreceptors to infect primary cells. Inhibition data suggest that CCR8 and an as yet unknown coreceptor can mediate HIV-1 entry for these two isolates, respectively. Such isolates would be expected to be refractory to inhibition by agents directed at CCR5 and CXCR4.

CM4, an R5 isolate able to utilize Bob/GPR15, on transfected cell lines was isolated from a patient with advanced HIV disease. Its insensitivity to both CCR5 and CXCR4 inhibitors suggested that it could use an alternate coreceptor to infect PBMC. This receptor is apparently also present on $\Delta 32/\Delta 32$ CCR5 PBMC and can support high levels of replication. Whether CM4 is able to use Bob/ GPR15 on primary cells remains to be determined. Bob/ GPR15 is an orphan G-protein coupled receptor whose mRNA is widely expressed in the colon, spleen, PHA stimulated PBMC, purified T-cells and to a lesser extent in unstimulated PBMC (Deng et al., 1997). Until a natural ligand to Bob/GPR15 is identified, it will remain difficult to prove that CM4 is using this receptor to enter primary cells. In a previous study, a different batch of CM4 (CM4-P1) was inhibited by RANTES, PRO140 and TAK779 suggesting that entry was CCR5-dependent (Trkola et al., 2001). For the experiments reported here, CM4 had been expanded in PHA-stimulated PBMC to generate a high titer stock (CM4-P2). The entry of this virus preparation was found to be independent of CCR5, as reflected by its ability to grow in $\Delta 32/\Delta 32$ CCR5 PBMC. Experiments directly comparing the properties of the original (CM4-P1) and expanded viral stock (CM4-P2) confirmed these findings (data not shown). The envelope sequences of CM4-P1 and CM4-P2 showed

that they were more than 99% identical (Fig. 1A). It is unlikely that the single amino acid change T300N between CM4-P1 and CM4-P2 is responsible for the altered coreceptor phenotype. It is more likely that the ability of CM4-P2 to grow in $\Delta 32/\Delta 32$ CCR5 PBMC is related to the viral titer, the ability to use alternate coreceptors being only revealed when the viral titer is high. Nevertheless, we cannot formally rule out that the ability of CM4 to replicate in $\Delta 32/$ Δ 32 CCR5 PBMC, presumably by alternate coreceptor-use, was acquired or selected for during in vitro passage.

CM9, an R5X4 virus, was also isolated from a patient with advanced HIV infection and it too is a pleiotropic isolate that has a preference for CXCR4-usage (Cilliers et al., 2003). Other studies have shown that CXCR4 is the coreceptor of preference for most R5X4 isolates, which explains why many are completely inhibited by AMD3100 (Yi et al., 1999). CM9 was previously shown to use alternate coreceptors, CCR3, CXCR6 and Bob/GPR15 albeit less efficiently than CXCR4 (Cilliers et al., 2003). In this study, we show that in addition to using these five coreceptors, CM9 can also use CCR8. This was confirmed using NP2/ CD4/CCR8 transfected cells, which supported CM9 replication to high levels (Fig. 4). However, the use of CCR8 appeared to be less efficient on PBMC compared to transfected cell lines, similar to CCR5 usage by this isolate. Thus, during the first 6 days, replication of CM9 in PBMC was fully inhibited by AMD3100, suggesting a dominant role of CXCR4. However, replication at later time points was inhibited by both vMIP-1 and I309, a CCR8-specific inhibitor, in the presence of AMD3100. Thus, it appears that growth in the presence of AMD3100 after 6 days is due to the ability of this isolate to use CCR8. This later use of CCR8 may be related to expression levels of this receptor on PBMC, which may vary in culture, or the utilization of CCR8 by different populations in the CM9 stock, or less efficient usage of CCR8 compared to CXCR4. CCR8 is expressed on primary lymphocytes and at high level in the thymus and has the ability to facilitate HIV-1 entry into thymocytes (Baecher-Allan et al., 2001; Dieckmann et al., 2001; Iellem et al., 2001; Lee et al., 2000). This receptor has

100000

10000

100

NP2/CD4/-

been reported to be used by a handful of simian immunodeficiency virus (SIV), HIV-1 and HIV-2 isolates and is one of the more commonly used alternate coreceptors (Horuk et al., 1998; Rucker et al., 1997). However, most of the above studies were performed only on cell lines, raising questions as to the significance of the findings for understanding replication in primary cells. Our finding that CM9 uses CCR8 on primary cells suggests that CCR8 may indeed prove to be a significant HIV-1 coreceptor for some isolates, a factor that may need to be taken into consideration in clinical studies of CCR5 and CXCR4 inhibitors. Chemokines that target CCR8, such as I309 may need to be considered for drug development.

Analysis of envelope sequences from viruses grown in PBMC and cell lines revealed that the same viral population of CM4 was able to use CCR5, Bob/GPR15 and a coreceptor on CCR5 deficient PBMC. In contrast, distinct viral populations may account for some of the promiscuous coreceptor activity of CM9. Two distinct viral populations could be discerned in gp160 from CM9. The population able to use CCR5, CXCR6 or CCR3 had three amino acid changes in the V3 region and 4 amino acid changes in V2 compared to the population able to utilize CXCR4 or Bob/ GPR15. However, the population able to utilize Bob/GPR15 also had an insertion in the gp41 similar to that found in the CCR5, CXCR6 and CCR3-using virus. This suggests that the Bob/GPR15 utilizing envelope is distinct from all the other populations; it even may be a recombinant between different populations. Further studies on this virus may provide clues as to the genetic determinants of both major and alternate coreceptor usage. The CCR8-using virus is likely to be a subpopulation different than the one that uses CXCR4, as the usage of the latter coreceptor was effectively inhibited up to day 6 in a PBMC culture. Hence, the sequence analysis performed on CM9 grown in the different cell lines may not be used to conclusively indicate which viral population accounts for use of the CCR8 receptor on $\Delta 32/\Delta 32$ CCR5 PBMC.

Whether it is significant that both the CM4 and the CM9 isolates were derived from patients with cryptococcal



Fig. 4. Replication of CM9 in human glioma NP-2 cell line expressing CD4 with either CCR5, CXCR4 or CCR8. Cells were infected and stained with anti-p24 monoclonal antibody and a B-galactosidase conjugated secondary antibody. Infected cells were stained with X-gal and the number of infectious foci counted. Mean of 2 independent experiments.

NP2/CD4/CCR5 NP2/CD4/CXCR4 NP2/CD4/CCR8

meningitis still remains unclear. Cryptococcal meningitis is a severe AIDS condition that arises after the immune system has deteriorated and it is associated with high levels of viral replication in blood and cerebrospinal fluid (Morris et al., 1998). It is possible that when CD4 target cells are limited, HIV-1 isolates exploit other receptors to maintain high levels of replication. Alternatively, cryptococcal meningitis could up-regulate other chemokine receptors or allow access of HIV-1 to other cell populations, such as in the central nervous system that may promote use of alternate coreceptors. These data may also point to the need for the use of a combination of entry inhibitors that target different stages in the entry cycle, such as the CD4-binding site or the fusion process. Enfuvirtide was able to efficiently inhibit both CM4 and CM9 strains suggesting that it is not influenced by alternate coreceptor usage. Thus, ENF may be a useful adjunct to coreceptor inhibitors (Tremblay et al., 2000, 2002). Collectively, these data suggest that alternate coreceptors need to be considered when developing entry inhibitors and that such isolates pose a threat to the clinical use of inhibitors targeting only CCR5 and CXCR4.

Materials and methods

HIV-1 viral isolates

Two previously described isolates, CM4 (99ZACM4) and CM9 (99ZACM9) from a cohort of AIDS patients, were selected for further analysis (Bredell et al., 2002; Cilliers et al., 2003; Papathanasopoulos et al., 2002; Trkola et al., 2001). CM4 was isolated in 1999 from a 34-year old male in Johannesburg, South Africa who had advanced HIV infection and cryptococcal meningitis. This patient had a viral load of 163,755 HIV-1 RNA copies/ml (by bDNA assay) and CD4 count of 47 cells/µl. CM9 was isolated in 1999 from a 30-year old female also with cryptococcal meningitis and with a CD4 count of 24 cells/µl. No viral load was available for this patient. Viral isolates were generated from both patients in a previous study using peripheral blood mononuclear cells (PBMC) cocultured with phytohemagglutinin (PHA)-activated donor PBMC (Cilliers et al., 2003). CM4-P1 was the first isolation reported in a previous publication (Trkola et al., 2001), which was later re-expanded using PHA-stimulated PBMC and IL-2 to generate high titer stocks for these experiments (CM4-P2). The gp160 encoding regions of both CM4-P1 and CM4-P2 were sequenced and shown to be more than 99% identical (Fig. 1A). CM4 was reported initially as an env subtype C by HMA (Bredell et al., 2002), but subsequent sequence analysis indicated that this virus was a complex recombinant of at least five different subtypes with multiple breakpoints in the env region (Papathanasopoulos et al., 2002). CM9 was subtype C throughout the genome (Papathanasopoulos et al., 2002). Ethical clearance for this study was obtained from the University of the Witwatersrand Committee for Research on Human Subjects (Medical).

Coreceptor assays on cell lines

Both viruses were tested for their ability to replicate in U87.CD4 cells transfected with either CCR5 or CXCR4 cells as previously described (Cilliers et al., 2003). In addition, U87.CD4 cell lines expressing CCR1 and GHOST.3 cell lines expressing Bob/GPR15, CCR1, CCR3 and CXCR6 were used to measure alternate coreceptor usage. Because all GHOST.3 cell lines express endogenous CXCR4, it was necessary to add 1.3 µM of AMD3100 to block this activity (Zhang and Moore, 1999). Viral replication was measured using an in-house p24 antigen assay (Trkola et al., 2001). Increasing p24 antigen levels in the presence of AMD3100 therefore indicated use of the transfected coreceptor. To measure CCR8-dependent replication, we used NP2/CD4 cells expressing CCR5, CXCR4 or CCR8 (Soda et al., 1999). For this, we used immunostaining as previously described (Clapham et al., 1992). HIV infected cells were fixed and stained with anti-HIV-1 p24 monoclonal antibodies (provided by the Centralised Facility for AIDS Reagents, UK) and anti-mouse Fab'2 fragments conjugated to β-galactosidase (Southern Biotechnology Associates, Inc.). Infected cells stained blue on addition of X-gal substrate (0.5 mg/ml 5-bromo-4-chloro-3-indolyl-bgalactopyranoside; Fisher Bioreagents Inc., 3 mM potassium ferrocyanide, 3 mM potassium ferricyanide and 1 mM magnesium chloride). Groups of blue-stained cells were regarded as foci of infection, and virus infectivity was estimated as FFU per milliliter (FFU/ml).

△32/△32 CCR5 PBMC cell preparation

Blood was drawn from two individuals identified with the $\Delta 32/\Delta 32$ CCR5 mutation and PBMC isolated and stimulated with PHA and IL-2 as previously described (Cilliers et al., 2003; Willey et al., 2003). AMD3100 (1 μ M) was used to inhibit entry via CXCR4.

Entry inhibitor assays

Entry inhibitor assays were performed using PHAstimulated PBMC from wt/wt (wild-type/wild-type) CCR5 and $\Delta 32/\Delta 32$ CCR5 donor cells. Cells were incubated with the specific inhibitor for 1 h before adding 1000 50% tissue culture infectious dose (TCID₅₀) per ml of virus evaluated on PBMC cultures. Assays were performed on 96 well plates using RPMI 1640, 10% fetal calf serum and IL-2 as previously described (Cilliers et al., 2003; Willey et al., 2003). Inhibitors tested included the anti-CCR5 Mab PRO140 (Progenics Pharmaceuticals, New York), chemokines RANTES (PeproTech Inc., Rocky Hill, NJ), I309, eotaxin, vMIP-I and CXCL16 (all from R&D Systems, Inc.) and the small molecule CXCR4 antagonist, AMD3100 (AnorMED Inc., Langley, Canada). Viral replication was measured by p24 antigen production or reverse transcriptase (RT) activity using an RT-enzyme-linked immunosorbent assay (CavidiTech, Uppsala, Sweden). Enfuvirtide (ENF) (American Peptide Company and Hoffmann-La Roche, Palo Alto, Ca) was used as previously described (Cilliers et al., 2004).

RNA extraction and amplification of the gp160 region

HIV-1 viral RNA was extracted from 200 µl of culture supernatant from different cell lines using the MagNA Pure LC Total Nucleic Acid Isolation Kit and automated MagNA Pure LC Instrument (Roche Diagnostics GmbH, Mannheim, Germany). A reverse transcription step was performed and the cDNA was used to amplify the gp160 region with primers as previously described (Gao et al., 1996). PCR products were purified using the High Pure PCR Product Purification kit (Roche Diagnostics GmbH, Mannheim, Germany). Sequencing reactions were performed in a MicroAmp 96 well optical reaction plate using the ABI PRISM Big dye Terminator v3.0 Cycle Sequencing kit and ABI PRISM 3100 automated sequencer. Sequence analysis was performed using the Sequencher version 4.0 software (Gene Codes Corporation). The ClustalX program was used for alignments.

Acknowledgments

We would like to thank Progenics Pharmaceuticals for supplying PRO140. Coreceptor-transfected cell lines were obtained from the NIH Reference and Reagent Repository and the UK MRC AIDS Reagent Program. This work was funded by the Wellcome Trust, Poliomyelitis Research Foundation, Fogarty International Centre (TWO-0231), WHO-UNAIDS African AIDS Vaccine Program (AAVP), Bristol-Myers Squibb "Secure-the-Future" Grant (RES 200-01), a Bristol-Myers Unrestricted Research Grant (JPM) and the National Institutes of Health (R01 AI41420, P01 AI52048). LM is a Wellcome Trust International Senior Research Fellow in Biomedical Science in South Africa and JPM is a Stavros S. Niarchos Scholar. The Department of Microbiology and Immunology at the Weill Medical College gratefully acknowledges the support of the William Randolph Hearst Foundation. PRC is an Elizabeth Glaser Scientist and supported by NIH grants MH 64408 and AI062514. SW was supported by Pfizer Inc.

References

Azevedo-Pereira, J.M., Santos-Costa, Q., Mansinho, K., Moniz-Pereira, J., 2003. Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 313 (1), 136–146.

- Baecher-Allan, C., Brown, J.A., Freeman, G.J., Hafler, D.A., 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167 (3), 1245–1253.
- Bredell, H., Hunt, G., Casteling, A., Cilliers, T., Rademeyer, C., Coetzer, M., Miller, S., Johnson, D., Tiemessen, C.T., Martin, D.J., Williamson, C., Morris, L., 2002. HIV-1 subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res. Hum. Retrovir. 18 (9), 681–683.
- Cilliers, T., Nhlapo, J., Coetzer, M., Orlovic, D., Ketas, T., Olson, W.C., Moore, J.P., Trkola, A., Morris, L., 2003. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 77 (7), 4449–4456.
- Cilliers, T., Patience, T., Pillay, C., Papathanasopoulos, M., Morris, L., 2004. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res. Hum. Retrovir. 20 (5), 477–482.
- Clapham, P.R., McKnight, A., Weiss, R.A., 1992. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J. Virol. 66 (6), 3531–3537.
- Dairaghi, D.J., Fan, R.A., McMaster, B.E., Hanley, M.R., Schall, T.J., 1999. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J. Biol. Chem. 274 (31), 21569–21574.
- Deng, H.K., Unutmaz, D., KewalRamani, V.N., Littman, D.R., 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388 (6639), 296–300.
- Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., Schuler, G., 2001. Ex vivo isolation and characterization of CD4 (+)CD25 (+) T cells with regulatory properties from human blood. J. Exp. Med. 193 (11), 1303–1310.
- Doms, R.W., Moore, J.P., 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151 (2), F9-F14.
- Donzella, G.A., Schols, D., Lin, S.W., Este, J.A., Nagashima, K.A., Maddon, P.J., Allaway, G.P., Sakmar, T.P., Henson, G., De Clercq, E., Moore, J.P., 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4 (1), 72–77.
- Douek, D.C., Picker, L.J., Koup, R.A., 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21, 265–304.
- Edinger, A.L., Hoffman, T.L., Sharron, M., Lee, B., O'Dowd, B., Doms, R.W., 1998. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 249 (2), 367–378.
- Gao, F., Robertson, D.L., Morrison, S.G., Hui, H., Craig, S., Decker, J., Fultz, P.N., Girard, M., Shaw, G.M., Hahn, B.H., Sharp, P.M., 1996. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70 (10), 7013–7029.
- Hoffman, N.G., Seiller-Moiseiwitsch, F., Ahn, J., Walker, J.M., Swanstrom, R., 2002. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 76, 3852–3864.
- Horuk, R., Hesselgesser, J., Zhou, Y., Faulds, D., Halks-Miller, M., Harvey, S., Taub, D., Samson, M., Parmentier, M., Rucker, J., Doranz, B.J., Doms, R.W., 1998. The CC chemokine I-309 inhibits CCR8dependent infection by diverse HIV-1 strains. J. Biol. Chem. 273 (1), 386–391.
- Iellem, A., Mariani, M., Lang, R., Recalde, H., Panina-Bordignon, P., Sinigaglia, F., D'Ambrosio, D., 2001. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4 (+)CD25 (+) regulatory T cells. J. Exp. Med. 194 (6), 847–853.
- Lee, S., Tiffany, H.L., King, L., Murphy, P.M., Golding, H., Zaitseva, M.B., 2000. CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. J. Virol. 74 (15), 6946–6952.
- Moore, J.P., Doms, R.W., 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U.S.A. 100 (19), 10598-10602.

- Moore, J.P., Kitchen, S.G., Pugach, P., Zack, J.A., 2004. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 20 (1), 111–126.
- Morris, L., Silber, E., Sonnenberg, P., Eintracht, S., Nyoka, S., Lyons, S.F., Saffer, D., Koornhof, H., Martin, D.J., 1998. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J. Infect. Dis. 177 (2), 473–476.
- Olson, W.C., Rabut, G.E., Nagashima, K.A., Tran, D.N., Anselma, D.J., Monard, S.P., Segal, J.P., Thompson, D.A., Kajumo, F., Guo, Y., Moore, J.P., Maddon, P.J., Dragic, T., 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CCchemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 (5), 4145–4155.
- Papathanasopoulos, M.A., Cilliers, T., Morris, L., Mokili, J.L., Dowling, W., Birx, D.L., McCutchan, F.E., 2002. Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. AIDS Res. Hum. Retrovir. 18 (12), 879–886.
- Pohlmann, S., Krumbiegel, M., Kirchhoff, F., 1999. Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. J. Gen. Virol. 80 (Pt. 5), 1241–1251.
- Rucker, J., Edinger, A.L., Sharron, M., Samson, M., Lee, B., Berson, J.F., Yi, Y., Margulies, B., Collman, R.G., Doranz, B.J., Parmentier, M., Doms, R.W., 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71 (12), 8999–9007.
- Schols, D., Struyf, S., Van Damme, J., Este, J.A., Henson, G., De Clercq, E., 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186 (8), 1383–1388.
- Seibert, C., Sakmar, T.P., 2004. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10 (17), 2041–2062.
- Sharron, M., Pohlmann, S., Price, K., Lolis, E., Tsang, M., Kirchhoff, F., Doms, R.W., Lee, B., 2000. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 96 (1), 41–49.
- Simmons, G., Reeves, J.D., Hibbitts, S., Stine, J.T., Gray, P.W., Proudfoot, A.E., Clapham, P.R., 2000. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177, 112–126.
- Soda, Y., Shimizu, N., Jinno, A., Liu, H.Y., Kanbe, K., Kitamura, T., Hoshino, H., 1999. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem. Biophys. Res. Commun. 258 (2), 313–321.

- Tremblay, C.L., Kollmann, C., Giguel, F., Chou, T.C., Hirsch, M.S., 2000. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquired Immune Defic. Syndr. 25 (2), 99–102.
- Tremblay, C.L., Giguel, F., Kollmann, C., Guan, Y., Chou, T.C., Baroudy, B.M., Hirsch, M.S., 2002. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46 (5), 1336–1339.
- Trkola, A., Ketas, T.J., Nagashima, K.A., Zhao, L., Cilliers, T., Morris, L., Moore, J.P., Maddon, P.J., Olson, W.C., 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 (2), 579–588.
- Willey, S.J., Reeves, J.D., Hudson, R., Miyake, K., Dejucq, N., Schols, D., De Clercq, E., Bell, J., McKnight, A., Clapham, P.R., 2003. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J. Virol. 77 (11), 6138–6152.
- Wu, L., LaRosa, G., Kassam, N., Gordon, C.J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., Moore, J.P., Mackay, C.R., 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 (8), 1373–1381.
- Xiao, L., Rudolph, D.L., Owen, S.M., Spira, T.J., Lal, R.B., 1998. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 12 (13), F137–F143.
- Yi, Y., Isaacs, S.N., Williams, D.A., Frank, I., Schols, D., De Clercq, E., Kolson, D.L., Collman, R.G., 1999. Role of CXCR4 in cell– cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J. Virol. 73 (9), 7117–7125.
- Zhang, Y.J., Moore, J.P., 1999. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J. Virol. 73 (4), 3443–3448.
- Zhang, Y., Lou, B., Lal, R.B., Gettie, A., Marx, P.A., Moore, J.P., 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74 (15), 6893–6910.
- Zhang, Y.J., Zhang, L., Ketas, T., Korber, B.T., Moore, J.P., 2001. HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. AIDS Res. Hum. Retrovir. 17 (3), 217–227.